Menu
Recruiting NCT04629326

PD-L1 Targeting Molecular Imaging of Solid Tumors

No phase Interventional Gastrointestinal Tumors

For patients and families

In plain language

An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.

What is being studied
The protocol lists: 68Ga-WL12 PET/CT.
Who it may be relevant to
Registry conditions: Gastrointestinal Tumors. Basic parameters: from 18 years · All.
What needs checking
Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
Where it takes place
China
Next step
Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →

Unsure about the terms? Read our patient guide →

Overview

The objective of the study is to constrcut a noninvasive approach WL12 PET/CT to detect the PD-L1 expression of tumor lesions in patients with gastrointestinal tumors and to identify patients benefiting from anti-PD-1/L1 treatment.

Interventions

  • Other 68Ga-WL12 PET/CT
    WL12, labeled with PET radio-nuclide ( Ga-68 )will be used as a molecular imaging tracer for PET/CT scanning

Primary outcome measures

  • Standardized uptake value（SUV） [Time frame: 2 years]

Eligibility criteria

Inclusion criteria

  • 1\. Aged >18 years old; ECOG 0 or 1;
  • 2\. Patients with Gastrointestinal tumors;
  • 3\. Has at least one measurable target lesion according to Response Evaluation Criteria in Solid Tumors (RECIST V1.1);
  • 4\. life expectancy >=12 weeks.

Exclusion criteria

  • 1\. Significant hepatic or renal dysfunction;
  • 2\. Is pregnant or ready to pregnant;
  • 3\. Cannot keep their states for half an hour;
  • 4\. Refusal to join the clinical study;
  • 5\. Suffering from claustrophobia or other mental diseases;
  • 6\. Any other situation that researchers think it is not suitable to participate in the experiment.

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Healthy volunteers: No

Study design

Allocation
N/A
Model
Single group
Masking
Open label
Primary purpose
Diagnostic

Study locations

China · 1 center
  • Beijing Cancer Hospital — Beijing

Identifiers

NCT: NCT04629326 · WL12-Tumor

Primary sources (government registries)

View this study on ClinicalTrials.gov ↗